

Review of: "Risk of death derived from Hazard Ratio should not be communicated as Relative Risk reductions for death in cancer clinical trials. Intentional or inadvertent?"

Violante Di Donato¹

¹ Sapienza University of Rome

Potential competing interests: No potential competing interests to declare.

I read with great interest the manuscript, which is interesting enough to attract the readers' attention and offers a high-quality overview of the topic.

The abstract perfectly summarizes the contents of the manuscript and the tables and figures are clear and interesting. The introduction is satisfactory and the conclusions are supported by the data analysis.

Although the manuscript can be considered already of high quality, I would suggest taking into account the following minor recommendations:

- I would recommend stressing novel pieces of evidence about **high-risk HPV**-negative high-grade cervical dysplasia, which seems to have more favorable outcomes than patients with documented high-risk infection (PMID: 35742340).
- To improve comparison with existing literature, authors should amplify references (see PMID: 29958629)